ArticleAntimicrobial agents and chemotherapy2013
Fluconazole assists berberine to kill fluconazole-resistant Candida albicans.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 77 citations in OpenAlex.
- Berberine as a Promising Antifungal Agent: Insights into Molecular Mechanisms and Therapeutic Potential.ACS omega · 2026Review
- Article
- Multi-Omics Analyses Reveal the Antifungal Mechanism of Phenazine-1-Carboxylic Acid AgainstJournal of fungi (Basel, Switzerland) · 2025Article
- The in vitro activity of iron chelator deferiprone against Candida (Candidozyma) auris in combination with antifungal agents.Medical mycology · 2025Article
- Inhibitory effects of berberine on fungal growth, biofilm formation, virulence, and drug resistance as an antifungal drug and adjuvant with prospects for future applications.World journal of microbiology & biotechnology · 2024Review
- A mechanism study on the synergistic effects of rifapentine and fluconazole against fluconazole-resistantHeliyon · 2024Article
- Di-berberine conjugates as chemical probes of Pseudomonas aeruginosa MexXY-OprM efflux function and inhibition.npj antimicrobials and resistance · 2023Article
- Di-berberine conjugates as chemical probes ofbioRxiv : the preprint server for biology · 2023Article
- In silico molecular modelling studies and antibiofilm efficacy of shikonin against Candida albicans: mechanistic insight.Archives of microbiology · 2023Article
- Antifungal and Immunomodulatory Ingredients from Traditional Chinese Medicine.Antibiotics (Basel, Switzerland) · 2022Review
- Novel Preclinical Study of Galloylquinic Acid Compounds fromMicrobiology spectrum · 2022Article
- Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Elucidating the Eradication Mechanism of Perillyl Alcohol againstACS bio & med chem Au · 2022Article
- Study on the mechanisms of action of berberine combined with fluconazole against fluconazole-resistant strains ofFrontiers in microbiology · 2022Article
- Review on Plant-Based Management in Combating Antimicrobial Resistance - Mechanistic Perspective.Frontiers in pharmacology · 2022Review
- Natural products from traditional medicine as promising agents targeting at different stages of oral biofilm development.Frontiers in microbiology · 2022Review
- Metabolic, structural, and proteomic changes in Candida albicans cells induced by the protein-carbohydrate fraction of Dendrobaena veneta coelomic fluid.Scientific reports · 2021Article
- Underlying mechanisms of the effect of minocycline againstExperimental and therapeutic medicine · 2021Article
- Evaluation of Berberine as an Adjunct to TB Treatment.Frontiers in immunology · 2021Article
- Inhibition of berberine hydrochloride on Candida albicans biofilm formation.Biotechnology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It was found in our previous study that berberine (BBR) and fluconazole (FLC) used concomitantly exhibited a synergism against FLC-resistant Candida albicans in vitro. The aim of the present study was to clarify how BBR and FLC worked synergistically and the underlying mechanism. Antifungal time-kill curves indicated that the synergistic effect of the two drugs was BBR dose dependent rather than FLC dose dependent. In addition, we found that BBR accumulated in C. albicans cells, especially in the nucleus, and resulted in cell cycle arrest and significant change in the transcription of cell cycle-related genes. Besides BBR, other DNA intercalators, including methylene blue, sanguinarine, and acridine orange, were all found to synergize with FLC against FLC-resistant C. albicans. Detection of intracellular BBR accumulation by fluorescence measurement showed that FLC played a role in increasing intracellular BBR concentration, probably due to its effect in disrupting the fungal cell membrane. Similar to the case with FLC, other antifungal agents acting on the cell membrane were able to synergize with BBR. Interestingly, we found that the efflux of intracellular BBR was FLC independent but strongly glucose dependent and associated with the drug efflux pump Cdr2p. These results suggest that BBR plays a major antifungal role in the synergism of FLC and BBR, while FLC plays a role in increasing the intracellular BBR concentration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.